•
Azenta Life Sciences (NASDAQ: AZTA) has entered into a global partnership with China-based Vazyme Biotech Co., Ltd (SHA: 688105) to enhance their joint “one-stop” service process. This collaboration covers a wide range of fields, including high-throughput sequencing, automated database building, raw material supply, experimental consumables, and sample storage. Financial details…
•
Hangzhou-based cell therapy specialist Yizun Biomedicine Co., Ltd has announced the completion of first patient enrollment and reinfusion in an investigator-initiated trial (ITT) for its CNK-UT cell therapy, targeting advanced solid tumors at Shulan Hangzhou Hospital. CNK-UT Cell Therapy: A Universal Cell Technology for Tumor TreatmentCNK-UT is a groundbreaking universal…